Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Verhoef, Daniël ^a   Visscher, Koen M ^b   Vosmeer, C Ruben ^b   Cheung, Ka Lei ^a   Reitsma, Pieter H ^a   Geerke, Daan P ^b   Bos, Mettine H A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; APIXABAN; BLOOD CLOTTING FACTOR 10A; EDOXABAN; ENZYME VARIANT; PHENYLALANINE; RIVAROXABAN; SNAKE VENOM; TYROSINE; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AMINO ACID; BLOOD; CHEMICAL BINDING; COAGULATION; GENETIC ENGINEERING; INHIBITOR; PLASMA;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOCIATION; DRUG BINDING; DRUG CONFORMATION; EMBRYO; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; IC50; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PARALOGY; PROTEIN ENGINEERING; STEREOSPECIFICITY; BLOOD CLOTTING TEST; CHEMISTRY; DRUG EFFECTS; GENETICS; KINETICS; METABOLISM;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR XA; FACTOR XA INHIBITORS; HUMANS; KINETICS; PROTEIN ENGINEERING;

EID: 85029327965     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00647-9     Document Type: Article

References (62)

1. Mann, K. G., Nesheim, M. E., Church, W. R., Haley, P. & Krishnaswamy, S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76, 1-16 (1990).
2. Bos, M. H. A., van 't Veer C. & Reitsma P. H. in Williams Hematology (eds Lichtman M. A. et al.) 1915-1948 (McGraw-Hill Education, 2015).
3. Camire, R. M. & Bos, M. H. The molecular basis of factor V and VIII procofactor activation. J. Thromb. Haemost. 7, 1951-1961 (2009).
4. Mann, K. G., Jenny, R. J. & Krishnaswamy, S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu. Rev. Biochem. 57, 915-956 (1988).
5. Hedstrom, L. Serine protease mechanism and specificity. Chem. Rev. 102, 4501-4524 (2002).
6. Krishnaswamy, S. Exosite-driven substrate specificity and function in coagulation. J. Thromb. Haemost. 3, 54-67 (2005).
7. Furie, B. et al. Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J. Biol. Chem. 257, 3875-3882 (1982).
8. Camire, R. M. Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site. J. Biol. Chem. 277, 37863-37870 (2002).
9. Toso, R., Zhu, H. & Camire, R. M. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J. Biol. Chem. 283, 18627-18635 (2008).
10. Girard, T. J. et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518-520 (1989).
11. Huntington, J. A., Read, R. J. & Carrell, R. W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923-926 (2000).
12. Pinto, D. J., Smallheer, J. M., Cheney, D. L., Knabb, R. M. & Wexler, R. R. Factor Xa inhibitors: next-generation antithrombotic agents. J. Med. Chem. 53, 6243-6274 (2010).
13. Roehrig, S. et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem. 48, 5900-5908 (2005).
14. Pinto, D. J. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50, 5339-5356 (2007).
15. Haginoya, N. et al. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element. J. Med. Chem. 47, 5167-5182 (2004).
16. Hopfner, K. P. et al. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure 7, 989-996 (1999).
17. Johnson, D. J., Langdown, J. & Huntington, J. A. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex. Proc. Natl Acad. Sci. USA 107, 645-650 (2010).
18. Bos, M. H. & Camire, R. M. Procoagulant adaptation of a blood coagulation prothrombinase-like enzyme complex in australian elapid venom. Toxins 2, 1554-1567 (2010).
19. Rao, V. S., Swarup, S. & Manjunatha Kini, R. The catalytic subunit of pseutarin C, a group C prothrombin activator from the venom of Pseudonaja textilis, is structurally similar to mammalian blood coagulation factor Xa. Thromb. Haemost. 92, 509-521 (2004).
20. Reza, M. A., Minh Le, T. N., Swarup, S. & Manjunatha Kini, R. Molecular evolution caught in action: gene duplication and evolution of molecular isoforms of prothrombin activators in Pseudonaja textilis (brown snake). J. Thromb. Haemost. 4, 1346-1353 (2006).
21. Skejic, J. & Hodgson, W. C. Population divergence in venom bioactivities of elapid snake Pseudonaja textilis: role of procoagulant proteins in rapid rodent prey incapacitation. PLoS ONE 8, e63988 (2013).
22. Lechtenberg, B. C. et al. Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. Blood 122, 2777-2783 (2013).
23. Toso, R. & Camire, R. M. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J. Biol. Chem. 279, 21643-21650 (2004).
24. Olson, S. T. et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb. Haemost. 92, 929-939 (2004).
25. Rezaie, A. R. Heparin-binding exosite of factor Xa. Trends Cardiovasc. Med. 10, 333-338 (2000).
26. Waxman, L., Smith, D. E., Arcuri, K. E. & Vlasuk, G. P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248, 593-596 (1990).
27. Burgering, M. J. et al. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. J. Mol. Biol. 269, 395-407 (1997).
28. Wei, A. et al. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. J. Mol. Biol. 283, 147-154 (1998).
29. Abdel-Azeim, S., Oliva, R., Chermak, E., De Cristofaro, R. & Cavallo, L. Molecular dynamics characterization of five pathogenic Factor X mutants associated with decreased catalytic activity. Biochemistry 53, 6992-7001 (2014).
30. Carvalho, A. L. et al. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. J. Mol. Biol. 322, 325-337 (2002).
31. Kita, M. et al. Blarina toxin, a mammalian lethal venom from the short-tailed shrew Blarina brevicauda: Isolation and characterization. Proc. Natl Acad. Sci. USA 101, 7542-7547 (2004).
32. Skala, W. et al. Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity. J. Biol. Chem. 289, 34267-34283 (2014).
33. Aminetzach, Y. T., Srouji, J. R., Kong, C. Y. & Hoekstra, H. E. Convergent evolution of novel protein function in shrew and lizard venom. Curr. Biol. 19, 1925-1931 (2009).
34. Hemker, H. C. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. 33, 4-15 (2003).
35. Schuijt, T. J. et al. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation 128, 254-266 (2013).
36. Baroni, M. et al. Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation. Biochim. Biophys. Acta 1854, 1351-1356 (2015).
37. Levigne, S. et al. Role of the alpha-helix 163-170 in factor Xa catalytic activity. J. Biol. Chem. 282, 31569-31579 (2007).
38. Ivanciu, L. & Camire, R. M. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood 126, 94-102 (2015).
39. Sorensen, A. B. et al. Molecular basis of enhanced activity in factor VIIa-trypsin variants conveys insights into tissue factor-mediated allosteric regulation of factor VIIa activity. J. Biol. Chem. 291, 4671-4683 (2016).
40. Gohara, D. W. & Di Cera, E. Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol. 29, 577-585 (2011).
41. Ruff, C. T., Giugliano, R. P. & Antman, E. M. Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents. Circulation 134, 248-261 (2016).
42. Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446-451 (2013).
43. Ansell, J. E. et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb. Haemost. 117, 238-245 (2016).
44. Thalji, N. K. et al. A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat. Med. 22, 924-932 (2016).
45. Frost, C. et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 76, 776-786 (2013).
46. Lip, G. Y. & Agnelli, G. Edoxaban: a focused review of its clinical pharmacology. Eur. Heart. J. 35, 1844-1855 (2014).
47. Camire, R. M., Larson, P. J., Stafford, D. W. & High, K. A. Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 39, 14322-14329 (2000).
48. Higgins, D. L. & Mann, K. G. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J. Biol. Chem. 258, 6503-6508 (1983).
49. Kleinegris, M. C. et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J. Thromb. Haemost. 12, 1647-1657 (2014).
50. Larson, P. J. et al. Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry 37, 5029-5038 (1998).
51. Bos, M. H. et al. Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations. Blood 114, 686-692 (2009).
52. Olson, S. T., Bjork, I. & Shore, J. D. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 222, 525-559 (1993).
53. Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19-25 (2015).
54. Korb, O., Stutzle, T. & Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J. Chem. Inf. Model. 49, 84-96 (2009).
55. Schmid, N. et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J. 40, 843-856 (2011).
56. Amini, M., Eastwood, J. W. & Hockney, R. W. Time integration in particle models. Comput. Phys. Commun. 44, 83-93 (1987).
57. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 01410 (2007).
58. Berendsen, H. J. C., Postma, J. P. M., Vangunsteren, W. F., Dinola, A. & Haak, J. R. Molecular-dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684-3690 (1984).
59. Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463-1472 (1997).
60. Pall, S. & Hess, B. A flexible algorithm for calculating pair interactions on SIMD architectures. Comput. Phys. Commun. 184, 2641-2650 (2013).
61. Darden, T. A. & Pedersen, L. G. Molecular modeling: an experimental tool. Environ. Health. Perspect. 101, 410-412 (1993).
62. Pryzdial, E. L. & Kessler, G. E. Kinetics of blood coagulation factor Xaalpha autoproteolytic conversion to factor Xabeta. Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity. J. Biol. Chem. 271, 16621-16626 (1996).